CHRONOS THERAPEUTICS
Chronos Therapeutics’ drug development scheme focuses in two main areas: - Repositioning FDA approved drugs. - Screening, discovery and development of novel proprietary drug candidates. Current Targets - Diseases of Ageing: Osteoporosis, Cancer and Sarcopenia. - Neurodegenerative Diseases: Parkinson’s Disease, Alzheimer’s Disease, ALS and Orphan Synucleopathies. Chronos Therapeutics’ research is successfully advancing from pre-clinical stages of development for age-related dise... ase treatments to clinical development. Chronos' pioneering drug discovery and development platform the Chronoscreen has enabled the company to quickly gain proprietary positions in the regulation of cellular chronological lifespan. Some of the most exciting and effective therapeutic approaches of the future will utilize our understanding of the biological programming of life-span and ageing that take place in every cell of our body. Harnessing this knowledge will lead to novel treatments for age related diseases such as Alzheimer's Disease, Diabetes, Cancer and Osteoporosis.
CHRONOS THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2009-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.chronostherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1865 309 500
Email Addresses:
[email protected]
Total Funding:
8 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt WordPress Wordpress Plugins Mobile Non Scaleable Content Nginx Sitelinks Search Box
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Ockham Biotech
Ockham Biotech is a research company which is focussed on the development of inhaled heparin for the treatment of airway diseases
Current Employees Featured
Investors List
University of Oxford
University of Oxford investment in Venture Round - Chronos Therapeutics
Vulpes Investment Management Pte Ltd
Vulpes Investment Management Pte Ltd investment in Venture Round - Chronos Therapeutics
Odey Asset Management
Odey Asset Management investment in Venture Round - Chronos Therapeutics
Official Site Inspections
http://www.chronostherapeutics.com
- Host name: pl1.jpcinet.co.uk
- IP address: 212.113.198.195
- Location: Crawley United Kingdom
- Latitude: 51.1149
- Longitude: -0.1841
- Timezone: Europe/London
- Postal: RH11
More informations about "Chronos Therapeutics"
Chronos Therapeutics - Crunchbase Company Profile
Organization. Chronos Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ...See details»
Chronos Therapeutics Company Profile | Management and
Www.chronostherapeutics.com . Chronos Therapeutics Profile and History. Chronos Therapeutics Ltd is a privately held biotechnology company focused on diseases of ageing, brain and …See details»
Chronos Therapeutics - Craft
Chronos Therapeutics is a biotechnology company operating a semi-virtual research and development model. It focuses on degenerative and behavioral diseases of the brain and …See details»
Chronos Therapeutics - LinkedIn
Chronos Therapeutics | 1,237 followers on LinkedIn. Chronos Ltd was a biotech company focused on developing therapeutics in degenerative and behavioural diseases of the brain and nervous …See details»
Chronos Therapeutics - PitchBook
Chronos Therapeutics General Information Description. Developer of therapeutic drugs intended to offer treatment for nervous system disorders. The company's services engage in the …See details»
TheraCryf | A clinical stage therapeutics company
Developing innovative therapeutics in oncology and behavioural brain disorders TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in …See details»
Chronos Therapeutics - Products, Competitors, Financials, …
Chronos Therapeutics is a biotechnology company specializing in the development of therapies for degenerative and behavioral brain diseases. Use the CB Insights Platform to explore …See details»
Chronos Therapeutics - M&A Summary and Business Overview
Www.chronostherapeutics.com. Profile M&A Activity (1) M&A Connections (1) Analytics Chronos Therapeutics Ltd. is a privately held biotechnology company focused on diseases of ageing, …See details»
Chronos Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore Chronos Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 2 news, and 3 literature, Technology Platform:Small ...See details»
Chronos Therapeutics | EU-Startups
Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system.See details»
Clyde & Co advises on the sale of Chronos Therapeutics to Evgen …
Mar 21, 2024 Clyde & Co has advised the majority shareholders on the sale of Chronos Therapeutics Limited ("Chronos") to Evgen Pharma plc, a clinical stage drug development …See details»
PRESS RELEASE - Chronos Therapeutics
[email protected] Notes to Editors About Chronos Therapeutics Chronos Therapeutics Ltd. is a privately held biotechnology company focused on diseases of ageing, …See details»
Chronos Integration Update – Company Announcement - FT.com
May 2, 2024 TheraCryf plc ("TheraCryf", the "Company" or the "Group") Update on integration of acquired company Chronos Therapeutics Limited Alderley Park, 2 May 2024 - TheraCryf plc …See details»
Shire takes stake in Chronos, hands over rights to three CNS …
Jul 20, 2016 For Chronos, the deal represents a way to immediately broaden its pipeline beyond preclinical amyotrophic lateral sclerosis asset RDC5. Chronos has been keen to achieve such …See details»
Chronos Therapeutics Ltd Completes Major Fund Raise in an Over ...
Oxford, UK 9th December 2013. Chronos Therapeutics Limited ("Chronos" or "the Company") is pleased to announce the completion of a major fundraising.See details»
Dr Chris Towler appointed Non-Executive Director
Jun 5, 2015 Chris is a highly experienced investment and pharmaceutical professional with decades of experience in each sector, most recently as director of OSEM (Oxford Spin Out …See details»
Chronos Therapeutics acquisitions bring hope for diseases of ageing
Transcript. By 2030, people aged 65 and up will account for nearly 20 percent of the world’s population. With the bulk of healthcare spending happening in old age, the potential for …See details»
Chronos CEO and VP Corporate Development interviewed by …
Jan 3, 2017 See the interview here. I consent to Chronos Therapeutics collecting my details through this form.See details»
Substantial Innovate UK grant awarded to broaden …
Dec 7, 2015 Chronos Therapeutics together with Prof Alison Woollard, of the Department of Biochemistry at the University of Oxford, has been successful in securing a substantial grant …See details»
Milestones Archives - Chronos Therapeutics
Chronos CEO, CSO and VP Corporate Development were interviewed at The Telegraph studios recently. Click here to see the interview on our approach to degenerative and behavioural …See details»